Nurix Therapeutics (NRIX) to Release Earnings on Tuesday

Nurix Therapeutics (NASDAQ:NRIX) is anticipated to announce its Q4 2025 results before the market opens on Tuesday, January 27th. Analysts expect the company to announce earnings of ($0.86) per share and revenue of $13.4140 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 12, 2026 at 12:00 AM ET.

Nurix Therapeutics Stock Up 1.9%

NRIX opened at $19.21 on Tuesday. The business’s fifty day simple moving average is $17.63 and its 200 day simple moving average is $13.01. Nurix Therapeutics has a 52 week low of $8.18 and a 52 week high of $22.50. The stock has a market cap of $1.48 billion, a PE ratio of -6.47 and a beta of 1.93.

Insider Buying and Selling at Nurix Therapeutics

In other Nurix Therapeutics news, insider Gwenn Hansen sold 4,087 shares of Nurix Therapeutics stock in a transaction that occurred on Thursday, October 30th. The shares were sold at an average price of $12.80, for a total transaction of $52,313.60. Following the completion of the sale, the insider directly owned 76,751 shares in the company, valued at approximately $982,412.80. The trade was a 5.06% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Houte Hans Van sold 6,284 shares of Nurix Therapeutics stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $12.56, for a total value of $78,927.04. Following the transaction, the chief financial officer owned 37,592 shares of the company’s stock, valued at approximately $472,155.52. This represents a 14.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 13,501 shares of company stock valued at $171,305. Company insiders own 7.40% of the company’s stock.

Institutional Trading of Nurix Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in NRIX. Jacobs Levy Equity Management Inc. purchased a new position in shares of Nurix Therapeutics during the 3rd quarter valued at approximately $405,000. Wexford Capital LP purchased a new position in Nurix Therapeutics in the 3rd quarter worth approximately $41,000. Velan Capital Investment Management LP increased its holdings in shares of Nurix Therapeutics by 60.0% in the third quarter. Velan Capital Investment Management LP now owns 16,000 shares of the company’s stock valued at $148,000 after purchasing an additional 6,000 shares during the last quarter. Vestal Point Capital LP lifted its position in Nurix Therapeutics by 73.8% during the third quarter. Vestal Point Capital LP now owns 3,475,000 shares of the company’s stock worth $32,109,000 after buying an additional 1,475,000 shares in the last quarter. Finally, Sherbrooke Park Advisers LLC purchased a new stake in Nurix Therapeutics in the 3rd quarter valued at $100,000.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on NRIX shares. Needham & Company LLC reissued a “buy” rating and set a $26.00 price objective on shares of Nurix Therapeutics in a report on Monday, December 8th. Wells Fargo & Company lifted their price target on shares of Nurix Therapeutics from $21.00 to $30.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 16th. Mizuho upped their price objective on shares of Nurix Therapeutics from $24.00 to $30.00 and gave the company an “outperform” rating in a research note on Wednesday, December 10th. Stifel Nicolaus set a $33.00 target price on shares of Nurix Therapeutics in a report on Friday, October 10th. Finally, Morgan Stanley set a $36.00 price target on shares of Nurix Therapeutics and gave the stock an “overweight” rating in a research note on Thursday, January 8th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Nurix Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.13.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.